Explore the Benefits of Biomarker Discovery in Early-Stage Drug Development
Developing and validating robust and sensitive biomarkers early in the oncology drug development process is key to progressing personalized medicine, as well as improving anticancer agent attrition rates. Clinical testing of these biomarkers, and associated CDx, is also facilitated, ultimately de-risking clinical trials.
This White Paper presents three biomarker discovery and validation strategies in early-stage oncology drug development through a systems biology approach. How to use translational preclinical models to identify and use biomarkers is highlighted, alongside methods to transfer preclinical biomarkers to the clinical space.
Download This White Paper to Understand How To:
- Use in vitro screening to generate biomarker sets, identify primary indications, and guide in vivo model selection
- Corroborate clinical observations using preclinical in vivo models, such as unique patient-derived xenografts (PDX), by exploring drug MoA
- Translate preclinical biomarkers into the clinic, enabling the accurate identification and stratification of clinical trial participants